|
|
| Line 3: |
Line 3: |
| | <StructureSection load='4ctj' size='340' side='right'caption='[[4ctj]], [[Resolution|resolution]] 1.47Å' scene=''> | | <StructureSection load='4ctj' size='340' side='right'caption='[[4ctj]], [[Resolution|resolution]] 1.47Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4ctj]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Dengue_virus_3 Dengue virus 3]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CTJ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4CTJ FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4ctj]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Dengue_virus_3 Dengue virus 3]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CTJ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4CTJ FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3A9:2,3-DIHYDRO-1-BENZOFURAN-5-CARBOXYLIC+ACID'>3A9</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SAM:S-ADENOSYLMETHIONINE'>SAM</scene></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=3A9:2,3-DIHYDRO-1-BENZOFURAN-5-CARBOXYLIC+ACID'>3A9</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=SAM:S-ADENOSYLMETHIONINE'>SAM</scene></td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ctk|4ctk]]</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ctj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ctj OCA], [https://pdbe.org/4ctj PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ctj RCSB], [https://www.ebi.ac.uk/pdbsum/4ctj PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ctj ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ctj FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ctj OCA], [http://pdbe.org/4ctj PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ctj RCSB], [http://www.ebi.ac.uk/pdbsum/4ctj PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4ctj ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/A9LIE0_9FLAV A9LIE0_9FLAV]] Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes (By similarity).[SAAS:SAAS013754_004_099774] | + | [[https://www.uniprot.org/uniprot/A9LIE0_9FLAV A9LIE0_9FLAV]] Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes (By similarity).[SAAS:SAAS013754_004_099774] |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 25: |
Line 24: |
| | [[Category: Dengue virus 3]] | | [[Category: Dengue virus 3]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Barral, K]] | + | [[Category: Barral K]] |
| - | [[Category: Bricogne, G]] | + | [[Category: Bricogne G]] |
| - | [[Category: Sharff, A]] | + | [[Category: Sharff A]] |
| - | [[Category: Antiviral screening]]
| + | |
| - | [[Category: Fragment-based drug discovery]]
| + | |
| - | [[Category: Ns5 methyltransferase]]
| + | |
| - | [[Category: Transferase]]
| + | |
| Structural highlights
Function
[A9LIE0_9FLAV] Envelope protein E binding to host cell surface receptor is followed by virus internalization through clathrin-mediated endocytosis. Envelope protein E is subsequently involved in membrane fusion between virion and host late endosomes. Synthesized as a homodimer with prM which acts as a chaperone for envelope protein E. After cleavage of prM, envelope protein E dissociate from small envelope protein M and homodimerizes (By similarity).[SAAS:SAAS013754_004_099774]
Publication Abstract from PubMed
Seasonal and pandemic flaviviruses continue to be leading global health concerns. With the view to help drug discovery against Dengue virus (DENV), a fragment-based experimental approach was applied to identify small molecule ligands targeting two main components of the flavivirus replication complex: the NS3 helicase (Hel) and the NS5 mRNA methyltransferase (MTase) domains. A library of 500 drug-like fragments was first screened by thermal-shift assay (TSA) leading to the identification of 36 and 32 fragment hits binding Hel and MTase from DENV, respectively. In a second stage, we set up a fragment-based X-ray crystallographic screening (FBS-X) in order to provide both validated fragment hits and structural binding information. No fragment hit was confirmed for DENV Hel. In contrast, a total of seven fragments were identified as DENV MTase binders and structures of MTase-fragment hit complexes were solved at resolution at least 2.0A or better. All fragment hits identified contain either a five- or six-membered aromatic ring or both, and three novel binding sites were located on the MTase. To further characterize the fragment hits identified by TSA and FBS-X, we performed enzymatic assays to assess their inhibition effect on the N7- and 2'-O-MTase enzymatic activities: five of these fragment hits inhibit at least one of the two activities with IC50 ranging from 180muM to 9mM. This work validates the FBS-X strategy for identifying new anti-flaviviral hits targeting MTase, while Hel might not be an amenable target for fragment-based drug discovery (FBDD). This approach proved to be a fast and efficient screening method for FBDD target validation and discovery of starting hits for the development of higher affinity molecules that bind to novel allosteric sites.
Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.,Coutard B, Decroly E, Li C, Sharff A, Lescar J, Bricogne G, Barral K Antiviral Res. 2014 Apr 1. pii: S0166-3542(14)00087-4. doi:, 10.1016/j.antiviral.2014.03.013. PMID:24704437[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Coutard B, Decroly E, Li C, Sharff A, Lescar J, Bricogne G, Barral K. Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. Antiviral Res. 2014 Apr 1. pii: S0166-3542(14)00087-4. doi:, 10.1016/j.antiviral.2014.03.013. PMID:24704437 doi:http://dx.doi.org/10.1016/j.antiviral.2014.03.013
|
